Rheumatoid Arthritis: Management & Treatment

Treatment Goals

1. NSAIDs (symptom relief only)
2. Glucocorticoids (bridge/adjunct)
3. DMARDs — conventional (csDMARDs), biologic (bDMARDs), and targeted synthetic (tsDMARDs)

Management Algorithm

1. NSAIDs

• COX-2 selective agents (e.g., celecoxib): less GI bleeding risk, but potential cardiovascular toxicity is a concern since RA patients already have elevated CV risk. Keep at low dose.
• Add a proton pump inhibitor in all RA patients taking NSAIDs.
• Monitor for reduced renal blood flow and elevated blood pressure.

2. Glucocorticoids

• ≥25% increased risk of serious infection at doses as low as 5 mg/day
• Risk doubles at 5–10 mg/day

• Use as bridge therapy while slower-acting DMARDs take effect (2–6 months onset)
• Prednisone ≤10 mg/day — rarely exceed this for articular manifestations
• Starting prednisone at DMARD initiation reduces erosive damage, disease activity, disability, and the need for biologic escalation at 2 years
• Taper to the lowest effective dose as soon as possible
• Intramuscular depot injections and intra-articular injections (ultrasound-guided for difficult joints) are useful for flares
• Always prescribe osteoporosis prophylaxis (bisphosphonates, unless childbearing age)

3. Conventional DMARDs (csDMARDs)

4. Biologic DMARDs (bDMARDs)

• Biologics must not be combined with each other — significantly increases infection risk
• If fever or infectious symptoms develop, stop biologic until resolved
• TNF inhibitors can precipitate CHF, demyelinating syndromes, or lupus-like syndromes
• Biosimilars (bsDMARDs) approved by EMA/FDA are interchangeable options

5. Targeted Synthetic DMARDs — JAK Inhibitors (tsDMARDs)

⚠️ Efficacy and safety of bDMARDs after JAK inhibitor failure, or JAK inhibitor after another JAK inhibitor, are not fully established.

6. Order of Therapy (EULAR 2019 Framework)

Step 1: Early RA → Start methotrexate ± short-term glucocorticoid bridge
         ↓  (reassess at 3 months; change if <50% improvement)
Step 2: csDMARD inadequate → Add/switch to another csDMARD (triple therapy)
         OR
         Add a bDMARD (TNF inhibitor, IL-6Ri, abatacept, rituximab)
         OR
         Add a tsDMARD (JAK inhibitor)
         ↓  (reassess; target remission by 6 months)
Step 3: Refractory RA → Most effective DMARD single or combination
         Consider surgical intervention for mechanical joint problems

7. Non-Pharmacological Measures

• Patient education — essential at diagnosis
• Physical therapy — preserve joint function, prevent deformity
• Occupational therapy — adaptive equipment, joint protection
• Rehabilitative measures — throughout the disease course
• Surgical intervention — for persistent active disease with mechanical joint failure (synovectomy, joint replacement)

Monitoring Summary

Seminar Questions: Approach to a Patient of Snake Bite

🔬 Venom Pharmacology & Classification

🚨 First Aid — Myths vs Evidence

🏥 Clinical Assessment & Grading

💉 Antivenom — Indications, Administration & Complications

🫀 Systemic Complications

🧠 Neurotoxic Envenomation (Elapids)

⚗️ Controversial & Higher-Order Questions

🌍 Epidemiology & Global Perspective

Neostigmine + Atropine in Cobra Bite: Mechanism & Clinical Use

Step 1 — Understanding the Target: The Neuromuscular Junction (NMJ)

1. A motor nerve impulse triggers release of acetylcholine (ACh) from the presynaptic terminal into the synaptic cleft
2. ACh diffuses across and binds to nicotinic ACh receptors (nAChR) on the postsynaptic muscle end plate
3. This opens ion channels → depolarization → muscle contraction
4. ACh is rapidly degraded by acetylcholinesterase (AChE) in the cleft, terminating the signal

Step 2 — What Cobra Venom Does

α-Neurotoxins (Postsynaptic) — the dominant toxin in cobras

• These are long-chain polypeptides (α-bungarotoxin family)
• They bind competitively to the nicotinic ACh receptor on the muscle end plate
• They physically occupy the receptor, blocking ACh from binding
• The NMJ is structurally intact — the receptor exists, the nerve terminal is undamaged — but ACh cannot activate it
• Result: flaccid paralysis — progressive, descending, beginning with cranial nerves (ptosis, ophthalmoplegia) → bulbar → respiratory muscles

β-Neurotoxins / Phospholipase A₂ (Presynaptic) — more prominent in kraits, some cobras

• These destroy the presynaptic nerve terminal — degrading the vesicle release machinery
• The axon must physically regrow to recover
• This damage is irreversible by any drug — recovery takes days to weeks
• Antivenom must be given before these toxins cause axon damage

Goldman-Cecil Medicine: "Once damaged by presynaptic neurotoxins, the axon must regrow, a process that can take days to weeks... In contrast, postsynaptic neurotoxins bind to the acetylcholine receptor on the muscle end plate external to the cell, so antivenom may reverse this type of paralysis."

Step 3 — The Pharmacological Rationale for Neostigmine

• ACh accumulates in the cleft and remains there much longer
• The elevated concentration of ACh competitively displaces the α-neurotoxin from the nAChR
• With enough ACh molecules present, some bind to any unoccupied or partially blocked receptors
• Net result: partial restoration of neuromuscular transmission → improvement in muscle strength

This is the same principle as using anticholinesterases in myasthenia gravis, where antibodies block nAChRs — cobra α-neurotoxin essentially produces a pharmacological myasthenia gravis.

Step 4 — Why Atropine Must Be Given First

• Prevent life-threatening bradycardia
• Prevent bronchospasm (critical in a patient already at risk of respiratory failure)
• Reduce secretions that could compromise the airway
• Allow neostigmine to exert its therapeutic effect at the NMJ freely

Step 5 — Clinical Protocol (Harrison's Principles, Table 471-2)

Step-by-step administration:

• Adults: 0.6 mg IV
• Children: 0.02 mg/kg IV (minimum 0.1 mg)

• Neostigmine: 0.02 mg/kg IV or IM (children: 0.04 mg/kg)
• Alternative: Edrophonium 10 mg IV (shorter acting, used as a diagnostic test dose)

• If objective improvement is seen (e.g., ptosis improves, power returns) → respond to maintenance dosing
• If no improvement → presynaptic toxin is likely dominant; drug will not help further; focus on ventilatory support

• Neostigmine: 0.5 mg IV/IM/SC every 1 hour as needed
• Atropine: 0.6 mg as continuous IV infusion over 8 hours (children: 0.02 mg/kg over 8 h)

Summary: What Each Drug Does

Critical Limitations

1. Works only for postsynaptic neurotoxins (α-type) — cobra is a good candidate; krait (predominantly β-neurotoxin) responds poorly
2. Not a substitute for antivenom — antivenom should always be given first if available; neostigmine buys time or supplements antivenom effect
3. Not a substitute for intubation — if the airway is at risk, secure it; neostigmine cannot be relied upon to maintain ventilation
4. Edrophonium test (short-acting) can be used diagnostically first — if there is clear improvement within minutes, it confirms postsynaptic mechanism and guides you to proceed with neostigmine maintenance

Drugs That Can Cause Dystonia

Pathophysiological Basis

Drug Classes Causing Dystonia

1. Antipsychotics (Most Common Cause)

Stahl's: "Exposure to D2 blockers, especially those with neither serotonergic nor anticholinergic properties, can cause dystonia, often upon first exposure."

• Acute dystonia — within 48 hours of starting or rapid dose increase; responds to anticholinergics
• Tardive dystonia — after >1 year of chronic use; anticholinergics are less effective and may worsen it

2. Antiemetics (D2 Antagonists — Frequently Overlooked)

3. Dopaminergic Agents (Paradoxical / Dose-Related)

4. Antiepileptics

5. Antidepressants

6. Mood Stabilizers

7. Stimulants / Drugs of Abuse

8. Other Drugs

Quick Reference Table

Acute Drug-Induced Dystonia: Treatment

Response is typically seen within 20 minutes of anticholinergic administration.

Trihexyphenidyl: Renal Clearance & Pharmacokinetics

Short Answer

What Is Known About Its Pharmacokinetics

Absorption

• Rapidly absorbed from the GI tract after oral administration
• Onset of action: within 1 hour of oral dosing
• Peak plasma levels: 2–3 hours post-dose
• Duration of action: 6–12 hours

Distribution

• Highly lipophilic → crosses the blood–brain barrier readily
• Significant CNS penetration within 30–60 minutes
• Large volume of distribution (Vd) — characteristic of the entire anticholinergic class used in Parkinson disease
• Plasma protein binding: poorly characterized

Metabolism

• Extensively metabolized — primarily via N-dealkylation and hydroxylation
• Relatively low clearance relative to hepatic blood flow (i.e., it is not a high-extraction hepatic drug — metabolism is capacity-limited rather than flow-limited)

Elimination

• Parent drug and metabolites excreted in both urine and bile (dual route)
• Elimination half-life: ~3.7 hours (Burke & Fahn, 1985 — the key primary PK study in dystonic patients)
• Elimination follows first-order kinetics
• No significant accumulation demonstrated; half-life independent of age, peak level, or duration of therapy in the Burke & Fahn study

The Renal Clearance Data Gap

"There is little pharmacokinetic information available for these drugs... the available information suggests that excretion of parent drug and metabolite is via the urine and bile."

"There is limited information available regarding the pharmacokinetics of these drugs, especially among older adults."

• Specific renal clearance values (mL/min) have not been formally established for trihexyphenidyl in the published literature
• Unlike drugs where renal clearance dominates (e.g., lithium, digoxin, aminoglycosides), trihexyphenidyl's primary elimination route is hepatic, not renal
• Urinary excretion represents a secondary route for metabolites, not selective glomerular filtration of intact drug

Clinical Implications

Summary